Clinical Trials Browser

Withdrawn × INDUSTRY × 130-nm albumin-bound paclitaxel × Clear all

NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT06592664 2025-06-06

FORTIFIDE

Phase 1/2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03169790 2025-02-24

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Phase 1/2 Withdrawn

Lymphoma, Non-Hodgkin

NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Merkel Cell

NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Melanoma

NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1/2 Withdrawn

Triple Negative Breast Neoplasms

NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Transitional Cell

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05791097 2023-07-24

AdvanTIG-306

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT01933061 2014-02-04

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Phase 2 Withdrawn

Melanoma